SCHEMBL1634576

SCHEMBL1634576

NS(=O)(=O)c1ccc(Nc2ncc3ccccc3n2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 3/20 0.58
CDK2 P24941 3/20 0.56
CCNA2 P20248 2/20 0.56
CCNT1 O60563 2/20 0.55
CDK1 P06493 2/20 0.55
CCNB1 P14635 2/20 0.55
CDK7 P50613 2/20 0.55
CDK9 P50750 2/20 0.55
CCNH P51946 2/20 0.55
CA1 P00915 10/20 0.55
CA2 P00918 10/20 0.55
CA9 Q16790 10/20 0.55
CA12 O43570 6/20 0.55
DKK1 O94907 1/20 0.54
GSK3B P49841 1/20 0.54
AURKA O14965 1/20 0.54
AURKB Q96GD4 1/20 0.54
CA4 P22748 4/20 0.52
CA14 Q9ULX7 3/20 0.52
CA6 P23280 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1633261 0.82 IKBKB (0.55) IKBKBCDK2CCNA2CCNT1CDK1
SCHEMBL1571117 0.82 IKBKB (0.55) IKBKBCDK2CCNA2CCNT1CDK1
SCHEMBL1571457 0.81 CDK1 (0.51) IKBKBCDK2CCNA2CCNT1CDK1
SCHEMBL1866178 0.81 CDK2 (0.59) IKBKBCDK2CCNA2CCNT1CDK1
SCHEMBL1570769 0.81 CA2 (0.52) IKBKBCDK2CCNA2CCNT1CDK1
SCHEMBL1631544 0.81 CDK1 (0.51) IKBKBCDK2CCNT1CDK1CCNB1
SCHEMBL14146534 0.81 CDK2 (0.51) IKBKBCDK2CCNA2CCNT1CDK1
SCHEMBL1634724 0.81 IKBKB (0.62) IKBKBCDK2CCNA2CCNT1CDK1
SCHEMBL1633147 0.81 CDK1 (0.53) IKBKBCDK2CCNT1CDK1CCNB1
SCHEMBL1571418 0.80 AURKA (0.57) IKBKBCDK2CCNA2CCNT1CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed
US-7932262-B2 Quinazolines for PDK1 inhibition NOVARTIS AG (CH) 2011-04-26 US disclosed
US-20100048561-A1 QUINAZOLINES FOR PDK1 INHIBITION NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2010-02-25 US disclosed
EP-2004615-A2 QUINAZOLINES FOR PDK1 INHIBITION Novartis AG (CH) 2008-12-24 EP disclosed
WO-2007117607-A9 QUINAZOLINES FOR PDK1 INHIBITION NOVARTIS VACCINES & DIAGNOSTIC (US) 2008-03-06 WO disclosed
WO-2007117607-A2 QUINAZOLINES FOR PDK1 INHIBITION NOVARTIS AG (CH) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048561-A1 QUINAZOLINES FOR PDK1 INHIBITION PDK1, PDK2, PDK3 IKBKB 980/4885CDK2 29/4885CCNA2 731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.